Exalenz Bioscience Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exalenz Bioscience Ltd.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Minimally-Invasive Surgery. SuturTek develops and manufactures mechanical suturing technology and devices for minimally-invasive surgery. Its products allow surgeons to suture quickly without holding and manipulating needles by hand and without the use of needle holders. SuturTek is focusing initially on cardiovascular surgery.
After years of working quietly while others promoted the opportunity in minimally-invasive cardiac surgery, Heartport is ready to play. But can it take back the field?
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.